Characterization of Novel PI3KÎ´ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies.

Haselmayer, Philipp; Camps, Montserrat; Muzerelle, Mathilde; El Bawab, Samer; Waltzinger, Caroline; Bruns, Lisa; Abla, Nada; Polokoff, Mark A; Jond-Necand, Carole; Gaudet, Marilène; Benoit, Audrey; Bertschy Meier, Dominique; Martin, Catherine; Gretener, Denise; Lombardi, Maria Stella; Grenningloh, Roland; Ladel, Christoph; Petersen, Jørgen Søberg; Gaillard, Pascale; Ji, Hong

Haselmayer, Philipp; Camps, Montserrat; Muzerelle, Mathilde; El Bawab, Samer; Waltzinger, Caroline; Bruns, Lisa; Abla, Nada; Polokoff, Mark A; Jond-Necand, Carole; Gaudet, Marilène; Benoit, Audrey; Bertschy Meier, Dominique; Martin, Catherine; Gretener, Denise; Lombardi, Maria Stella; Grenningloh, Roland; Ladel, Christoph; Petersen, Jørgen Søberg; Gaillard, Pascale; Ji, Hong.

Afiliação

Haselmayer P; Immunology, Department of Preclinical Pharmacology, Merck Serono , Darmstadt , Germany ; Biologics and Immunology Platform, Merck Serono , Darmstadt , Germany.
Camps M; Department of Cellular Immunology, Merck Serono SA , Geneva , Switzerland ; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland.
Muzerelle M; Department of Chemistry, Merck Serono SA , Geneva , Switzerland.
El Bawab S; Drug Metabolism and Pharmacokinetics (DMPK), Non-Clinical Development, Merck Serono , Darmstadt , Germany.
Waltzinger C; Department of Cellular Immunology, Merck Serono SA , Geneva , Switzerland ; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland.
Bruns L; Immunology, Department of Preclinical Pharmacology, Merck Serono , Darmstadt , Germany ; Biologics and Immunology Platform, Merck Serono , Darmstadt , Germany.
Abla N; Drug Metabolism and Pharmacokinetics (DMPK), Non-Clinical Development, Merck Serono SA , Geneva , Switzerland.
Polokoff MA; BioSeek® Division, DiscoveRx Corporation , South San Francisco, CA , USA.
Jond-Necand C; Department of Cellular Immunology, Merck Serono SA , Geneva , Switzerland ; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland.
Gaudet M; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland ; Department of Early PK/PD Biomarker, Merck Serono SA , Geneva , Switzerland.
Benoit A; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland ; Department of Early PK/PD Biomarker, Merck Serono SA , Geneva , Switzerland.
Bertschy Meier D; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland ; Department of Early PK/PD Biomarker, Merck Serono SA , Geneva , Switzerland.
Martin C; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland ; Department of Early PK/PD Biomarker, Merck Serono SA , Geneva , Switzerland.
Gretener D; Department of Screening, Merck Serono SA , Geneva , Switzerland.
Lombardi MS; Department of Cellular Immunology, Merck Serono SA , Geneva , Switzerland ; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland.
Grenningloh R; Immunology, Department of Preclinical Pharmacology, EMD Serono Research and Development Institute , Billerica, MA , USA.
Ladel C; Biologics and Immunology Platform, Merck Serono , Darmstadt , Germany.
Petersen JS; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland.
Gaillard P; Department of Chemistry, Merck Serono SA , Geneva , Switzerland.
Ji H; Biologics and Immunology Platform, Merck Serono SA , Geneva , Switzerland ; Department of Early PK/PD Biomarker, Merck Serono SA , Geneva , Switzerland.